In the pirfenidone group , as compared with the placebo group , there was a relative reduction of 47.9 % in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died ; there was also a relative increase of 132.5 % in the proportion of patients with no decline in FVC ( P < 0.001 ) .